CLP

General Information


DRACP ID  DRACP00875

Peptide Name   CLP

Sequence  LP

Sequence Length  2

UniProt ID  Not available

PubChem CID  Not available

Origin  marine natural metabolite

Type  Native peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MDA-MB-231 Breast adenocarcinoma Carcinoma IC50=73.4 μM MTT assay 48h 1
MDA-MB-468 Breast adenocarcinoma Carcinoma IC50=67.4 μM MTT assay 48h 1

Hemolytic Activity  Human red blood cells (RBC): LC50>401 μM

Normal (non-cancerous) Cytotoxicity  MCF-12A: IC50>100 μM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00875

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  Not available

N-terminal Modification  Lactam

C-terminal Modification  Lactam

Other Modification  Lactam

Chiral  L



Physicochemical Information


Formula  C11H20N2O3

Absent amino acids  ACDEFGHIKMNQRSTVWY

Common amino acids  LP

Mass  24631

Pl  6.11

Basic residues  0

Acidic residues  0

Hydrophobic residues  1

Net charge  0

Boman Index  492

Hydrophobicity  110

Aliphatic Index  195

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 31669320

Title  Marine natural compound cyclo(L-leucyl-L-prolyl) peptide inhibits migration of triple negative breast cancer cells by disrupting interaction of CD151 and EGFR signaling

Doi 10.1016/j.cbi.2019.108872

Year  2020

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.